America Votes, China Plans
By James Strachan
November 3, 2026
China sets out its stall for global biopharmaceutical preeminence as the US faces further uncertainty over research funding and regulation
23 min read
False
Advertisement
Regulation & Standards
Can Clinical Trials Collect Less Data Without Compromising Safety?
By Mouj Hijazi
October 22, 2026
Rob DiCicco discusses how FDA–industry collaboration is helping sponsors rethink safety reporting, selective safety data collection, and pragmatic clinical trial design.
5 min read
Bringing CAR T Closer to Home
October 13, 2026
CAR T Vision aims to widen access to cell therapy by expanding community-based delivery, easing operational barriers, and building sustainable funding models
7 min read
Building a CAR-T CMC Strategy on a Limited Budget
By Kate Fynes
October 6, 2026
Early developers do not need a finalized commercial process before first-in-human studies, but they do need a clear plan for managing cost, scalability, comparability, and future manufacturing changes
7 min read
What Do Scientists Want from AI?
September 14, 2026
Scientists are already using AI in the lab – but many are doing so without the safeguards their employers may assume are in place
5 min read
China’s Biopharma Homecoming
By James Strachan, Henry Thomas
September 1, 2026
Chinese biopharma leaders are returning from the West to build a more confident – and innovative – global industry, says Cyagen’s Lance Han
7 min read
The Mindset for Success in Biopharma's New Multipolar World
By Jessica Allerton, James Strachan
August 18, 2026
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
10 min read
This Week’s CGT News: Gene-Editing Trial Death Raises Concerns
August 3, 2026
A previously undisclosed death in China raises questions about gene-editing oversight, deramiocel meets its Phase 3 Duchenne endpoint, and researchers identify a source of CAR NK dysfunction
4 min read
The Rise of China: From Science Cities to Global Ambition
By James Strachan, Kathryn Wighton
July 15, 2026
Daphne Smyth of Veristat on the rise of Chinese biopharma, regulatory realities, and what comes next
8 min read
FDA Selects Seven Companies for Drug Manufacturing Pilot
July 13, 2026
Selected companies will receive earlier FDA engagement to support new US drug manufacturing facilities across small molecules, biologics, sterile injectables, and advanced therapies
2 min read
